Through its support of cancer research fellowships, Santander is playing a crucial role in Mass General's development of new targeted cancer therapies.

Santander_logo_300x87When young cancer researchers have good ideas, keeping them working toward their goals is critical to success. That’s why support from corporate philanthropists, like Santander, plays a crucial role in advancing innovation with a program supporting research fellowships at Mass General Cancer Center.

Santander, through its Santander Universities Global Division is a long-time supporter of higher education around the world, with over 1,100 philanthropic agreements globally, including 35 in the United States. Santander established the Santander Hematology/Oncology Fellowship Program Fund in 2013 funding the research of scientists working in the laboratories at Massachusetts General Hospital, Harvard University and Massachusetts Institute of Technology.

“The Massachusetts General Hospital (MGH) Cancer Center is among the world’s most distinguished academic cancer centers, and is widely recognized for providing innovative treatments and compassionate care to pediatric, adolescent, and adult cancer patients,” said Eduardo Garrido, director, Santander Universities US. “We are proud to do our part by being the philanthropic sponsor of the Santander Hematology/Oncology Fellowship Program. In working together, we are moving one step closer to revolutionizing the future of cancer medicine.”

The goal is to devise targeted drug therapies to treat cancers that are resistant to traditional drugs.

Already in its second year of a four-year, $1 million commitment, Santander cancer research fellows are working to move beyond standard chemotherapies and radiation therapy to develop targeted cancer therapies by learning how cancer cells develop, multiply and die. The goal is to devise targeted drug therapies to treat cancers that are resistant to traditional drugs.

Generosity with Impact

“The generosity of organizations such as Santander allows our fellows to focus their energy where it can have the greatest impact,” says Peter L. Slavin, MD, president of Massachusetts General Hospital. “We’re grateful that Santander understands and shares a commitment to these efforts.”

Santander3
Santander is the lead sponsor of The Friends of the Mass General Cancer Center’s annual fall benefit: “Couture for Cancer Care: Celebrating Survivorship through Fashion.” Funds raised go toward supportive care programs.

Santander is a locally-focused bank backed by the strength of the Santander Group, a leading global financial institution.  In the United States, the company offers a broad spectrum of products and services for personal, business, and corporate banking customers.

Santander’s sponsorship of the cancer research fellowships comes at an important time when healthcare spending is tight and hospital margins are shrinking, says David Ryan, MD, chief of Hematology and Oncology at Mass General. The donation allows cancer research fellows to extend the length and depth of their work without having to divert time and resources to raising additional funding.

Promising Cancer Research

By supporting this program at the leading edge of cancer research at Mass General Cancer Center, Santander joins the innovation community of greater Boston in working to save lives.

Anna Farago, MD, PhD, one of the first cancer research fellows funded by the program, is working to improve therapies to fight small-cell lung cancer, an aggressive disease that accounts for about 15 percent of all lung cancers. She is studying which combinations of drugs are most effective and also investigating how tumors become resistant to the therapies used to treat them.

Aaron Hata, MD, PhD, another research fellow, is studying the mechanisms governing cell death in mutant non-small cell lung cancer, which represents 25% of all non-small cell lung cancer. Understanding why these cells are able to survive may lead to specific drug therapies to eradicate them.

By supporting this program at the leading edge of cancer research at Mass General Cancer Center, Santander joins the innovation community of greater Boston in working to save lives.

By supporting Mass General, your company can team with one of the world’s most prestigious academic medical centers to effect positive change. If you would like to learn more, we would be happy to speak with you. Please contact us today to start the conversation.